Search Results

You are looking at 61 - 70 of 1,145 items for :

  • "characteristics" x
  • All content x
Clear All
Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma

). Patient demographics and clinical characteristics are detailed in Table 1 . Of the patients, 98% were women, 78% were white, and 19.5% were black. Median age was 59.4 years (range, 50.7–67.7 years) at initiation of palbociclib treatment. Most patients (n

Full access

Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher

delivery of postoperative chemotherapy include clinical factors, such as patient age, extent of postoperative complications, and presence of lymph node metastases. 10 – 13 In contrast, sociodemographic characteristics influencing receipt of adjuvant

Full access

Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto, and Tatsuo Akechi

was taking was investigated by a review of the medical records. Table 1 Patient Demographics and Clinical Characteristics (N=106) Depression: Presence/absence of depression was assessed using the PHQ-9. 23 The PHQ-9 consists of 9

Full access

Antonious Hazim, Gordon Mills, Vinay Prasad, Alyson Haslam, and Emerson Y. Chen

involved CAR T-cell therapy. The most common cancer types were leukemia (16%), lung (12%), and breast (10%) ( Table 1 ). Table 1. Characteristics of Dose-Escalation Trials Of the 3,890 patients, 2,506 had both response and dose data, among whom the ORR (CR

Full access

Shehzad K. Niazi, Aaron Spaulding, Emily Brennan, Sarah K. Meier, Julia E. Crook, Lauren F. Cornell, Sikander Ailawadhi, Matthew M. Clark, and Teresa A. Rummans

Social Security Act) were invited to participate in the survey. The database contains information about hospital characteristics, services offered, and staffing, and responses are validated through review, comparison, and member checking by the AHA. 41

Full access

Marissa B. Lawson, Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone, Scott D. Ramsey, and Janie M. Lee

ICD codes to identify patients with screening encounters: Z12.31, V76.11, and V76.12. Statistical Analysis We compared clinical and tumor characteristics between women diagnosed with cancer who received screening mammography before diagnosis and those

Full access

Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung

,500 Commission on Cancer–accredited facilities. Jointly sponsored by the American College of Surgeons and American Cancer Society, it currently captures more than 70% of newly diagnosed cancers within the United States. Relevant patient characteristics, tumor

Full access

Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia, and Pierre I. Karakiewicz

data can provide further detail regarding the distribution of patient and renal cell carcinoma (RCC) characteristics within this special patient group. Based on these considerations, we reexamined patients with RCC with T1a 0- to 2-cm renal tumors to

Full access

Amit G. Singal, Jorge A. Marrero, and Adam Yopp

characteristics could not be determined. Patients with Child-Pugh C cirrhosis and those with poor performance status were also excluded, because surveillance is not recommended in these patients. This study was approved by the Institutional Review Board at UT

Full access

Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen

institutions. Patient demographics, disease characteristics (stage, histology, genomic alterations, metastatic burden [defined as the number of metastatic organ systems involved: 1, 2, ≥2]), treatment received (including ICIs and BMAs), PD-L1 status when known